{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:30:26Z","timestamp":1793741426367,"version":"4.6.1"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jns.2026.125787","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:26:43Z","timestamp":1770222403000},"page":"125787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The immune awakening: Transformative strategies against brain tumors"],"prefix":"10.1016","volume":"483","author":[{"given":"Ayesha","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyaba","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myda","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Wamiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Yousuf","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shafay","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125787_bb0005","series-title":"An Overview of Brain Tumor","author":"Pichaivel","year":"2022"},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0010","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjmed.2017.12.039","article-title":"Brain tumors","volume":"131","author":"McFaline-Figueroa","year":"2018","journal-title":"Am. J. Med."},{"issue":"5 Suppl","key":"10.1016\/j.jns.2026.125787_bb0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.jns.2026.125787_bb0020","unstructured":"Mellinghoff IK, Gilbertson RJ. Brain tumors: challenges and opportunities to cure. J. Clin. Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0025","series-title":"Principles of Neuro-Oncology","article-title":"Epidemiology of brain tumors","author":"Reynoso-Nover\u00f3n","year":"2021"},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1-2","key":"10.1016\/j.jns.2026.125787_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1013104423154","article-title":"Multidrug resistance in brain tumors: roles of the blood\u2013brain barrier","volume":"20","author":"R\u00e9gina","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jns.2026.125787_bb0040","article-title":"Advancements and challenges in brain cancer therapeutics","author":"Bai","year":"2024","journal-title":"Exploration"},{"key":"10.1016\/j.jns.2026.125787_bb0045","article-title":"Immunotherapy approaches in the treatment of malignant brain tumors","author":"Dunn-Pirio","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jns.2026.125787_bb0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11864-015-0371-3","article-title":"An update on the role of immunotherapy and vaccine strategies for primary brain tumors","volume":"16","author":"Neagu","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00603.x","article-title":"Immunotherapy of malignant brain tumors","volume":"222","author":"Mitchell","year":"2008","journal-title":"Immunol. Rev."},{"issue":"14","key":"10.1016\/j.jns.2026.125787_bb0060","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-13-2057","article-title":"Immunotherapy for brain cancer: recent progress and future promise","volume":"20","author":"Jackson","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0065","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/cei.13279","article-title":"Neuroimmunology \u2013 the past, present and future","volume":"197","author":"Nutma","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3171\/foc.2000.9.6.2","article-title":"Basic concepts of immunology and neuroimmunology","volume":"9","author":"Sehgal","year":"2000","journal-title":"Neurosurg. Focus"},{"issue":"5","key":"10.1016\/j.jns.2026.125787_bb0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1172\/JCI41911","article-title":"Trafficking of immune cells in the central nervous system","volume":"120","author":"Wilson","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.it.2015.08.006","article-title":"Revisiting the mechanisms of CNS immune privilege","volume":"36","author":"Louveau","year":"2015","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1084\/jem.20180199","article-title":"Immune cells and CNS physiology: microglia and beyond","volume":"216","author":"Norris","year":"2019","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0301-0082(98)00083-5","article-title":"The role of microglia and macrophages in the pathophysiology of the CNS","volume":"58","author":"Stoll","year":"1999","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/brain\/awad304","article-title":"Brain perivascular macrophages: current understanding and future prospects","volume":"147","author":"Wen","year":"2024","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2026.125787_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1098-1136(20000215)29:4<293::AID-GLIA1>3.0.CO;2-A","article-title":"Brain-immune connection: immuno-regulatory properties of CNS-resident cells","volume":"29","author":"Becher","year":"2000","journal-title":"Glia"},{"key":"10.1016\/j.jns.2026.125787_bb0105","series-title":"The Functional Roles of Glial Cells in Health and Disease","first-page":"93","article-title":"The role of microglia and astrocytes in CNS immune surveillance and immunopathology","author":"Aloisi","year":"1999"},{"issue":"9","key":"10.1016\/j.jns.2026.125787_bb0110","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1172\/JCI90603","article-title":"Understanding the functions and relationships of the glymphatic system and meningeal lymphatics","volume":"127","author":"Louveau","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2026.125787_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s42003-024-05911-5","article-title":"Glymphatic and lymphatic communication with systemic responses during physiological and pathological conditions in the central nervous system","volume":"7","author":"Licastro","year":"2024","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1515\/revneuro-2020-0106","article-title":"The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance","volume":"32","author":"Yankova","year":"2021","journal-title":"Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ni.3666","article-title":"The movers and shapers in immune privilege of the CNS","volume":"18","author":"Engelhardt","year":"2017","journal-title":"Nat. Immunol."},{"issue":"37","key":"10.1016\/j.jns.2026.125787_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav0492","article-title":"The anatomy and immunology of vasculature in the central nervous system","volume":"4","author":"Mastorakos","year":"2019","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2018.04.003","article-title":"Advances in meningeal immunity","volume":"24","author":"Rua","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/35100529","article-title":"Toll-like receptors and innate immunity","volume":"1","author":"Medzhitov","year":"2001","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","article-title":"Microglia biology: one century of evolving concepts","volume":"179","author":"Prinz","year":"2019","journal-title":"Cell"},{"issue":"5726","key":"10.1016\/j.jns.2026.125787_bb0150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ni.3102","article-title":"Innate immunity in Alzheimer's disease","volume":"16","author":"Heneka","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jns.2026.125787_bb0165","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-immunol-031210-101352","article-title":"Signaling by myeloid C-type lectin receptors in immunity and homeostasis","volume":"30","author":"Sancho","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jns.2026.125787_bb0170","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jns.2026.125787_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0180","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0185","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jns.2026.125787_bb0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/glia.23078","article-title":"Differential Kv1.3, KCa3.1, and Kir2.1 expression in \u201cclassically\u201d and \u201calternatively\u201d activated microglia","volume":"65","author":"Nguyen","year":"2017","journal-title":"Glia"},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0200","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1177\/1352458514533230","article-title":"The role of microglial activation in disease progression","volume":"20","author":"Correale","year":"2014","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0205","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1939601","article-title":"A novel miR1983-TLR7-IFN\u03b2 circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1","volume":"10","author":"Shah","year":"2021","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4049\/jimmunol.1900838","article-title":"Meningeal lymphatics: from anatomy to central nervous system immune surveillance","volume":"204","author":"Papadopoulos","year":"2020","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0215","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/s41593-019-0427-y","article-title":"T cells promote microglia-mediated synaptic elimination and cognitive dysfunction during recovery from neuropathogenic flaviviruses","volume":"22","author":"Garber","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2026.125787_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1360242","article-title":"B cells and the stressed brain: emerging evidence of neuroimmune interactions in the context of psychosocial stress and major depression","volume":"18","author":"Engler-Chiurazzi","year":"2024","journal-title":"Front. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.jns.2026.125787_bb0230","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","article-title":"PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation","volume":"1864","author":"Qiu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0235","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/neuonc\/noaa029","article-title":"The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction","volume":"22","author":"Himes","year":"2020","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0240","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","article-title":"Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation","volume":"44","author":"Estephan","year":"2025","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.jns.2026.125787_bb0250","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.7150\/thno.81407","article-title":"Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jns.2026.125787_bb0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2015.00153","article-title":"Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites","volume":"5","author":"Perng","year":"2015","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15698\/cst2019.02.176","article-title":"Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma","volume":"3","author":"Won","year":"2019","journal-title":"Cell Stress"},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0265","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0270","article-title":"Hypoxia-driven M2-polarized macrophages facilitate cancer aggressiveness and temozolomide resistance in glioblastoma","volume":"2022","author":"Zhang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"9","key":"10.1016\/j.jns.2026.125787_bb0275","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3390\/cells10092257","article-title":"The interplay between glioblastoma and its microenvironment","volume":"10","author":"Dapash","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jns.2026.125787_bb0280","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/08820139.2024.2337022","article-title":"GBM immunotherapy: macrophage impacts","volume":"53","author":"Loginova","year":"2024","journal-title":"Immunol. Invest."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0285","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163451","article-title":"Monocyte-neutrophil entanglement in glioblastoma","volume":"133","author":"Friedmann-Morvinski","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.jns.2026.125787_bb0290","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jns.2026.125787_bb0295","doi-asserted-by":"crossref","first-page":"1384249","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31340-1","article-title":"Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression","volume":"13","author":"Comba","year":"2022","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.jns.2026.125787_bb0305","article-title":"Spatiotemporal insights into glioma oncostream dynamics: unraveling formation, stability, and disassembly pathways","volume":"11","author":"Faisal","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"40","key":"10.1016\/j.jns.2026.125787_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3243","article-title":"G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy","volume":"7","author":"Alghamri","year":"2021","journal-title":"Sci Adv."},{"issue":"5","key":"10.1016\/j.jns.2026.125787_bb0315","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-024-01519-4","article-title":"Novel clinical trials and approaches in the management of glioblastoma","volume":"26","author":"Valerius","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jns.2026.125787_bb0320","series-title":"A 5-year Update on the Clinical Development of Cancer Cell-based Vaccines for Glioblastoma Multiforme","first-page":"376","volume":"18(3)","author":"Alkayyal","year":"2025"},{"key":"10.1016\/j.jns.2026.125787_bb0325","series-title":"Why Certain Brain Tumors Don't Respond to Immunotherapy","author":"Heady","year":"2023"},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0330","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44178-022-00021-w","article-title":"Peptide vaccine against glioblastoma: from bench to bedside","volume":"1","author":"Yang","year":"2022","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0345","doi-asserted-by":"crossref","DOI":"10.1358\/dof.2013.38.3.1933992","article-title":"Rindopepimut","author":"Gedeon","year":"2013","journal-title":"Drugs Future"},{"issue":"31","key":"10.1016\/j.jns.2026.125787_bb0350","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0355","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0360","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/cns.15.38","article-title":"ReACT phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma","volume":"5","author":"Gatson","year":"2016","journal-title":"CNS Oncol."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0370","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/14760584.2014.881255","article-title":"Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma","volume":"13","author":"Fenstermaker","year":"2014","journal-title":"Expert Rev. Vaccines"},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0375","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99145","article-title":"Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial","volume":"3","author":"Ji","year":"2018","journal-title":"JCI Insight"},{"issue":"19","key":"10.1016\/j.jns.2026.125787_bb0385","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A Cancer Research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0390","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/neuonc\/noz040","article-title":"Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients","volume":"21","author":"Migliorini","year":"2019","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0395","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/neuonc\/noad185","article-title":"A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas","volume":"26","author":"Saijo","year":"2023","journal-title":"Neuro Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2026.125787_bb0400","article-title":"Combination of the IMA950\/poly-ICLC multipeptide vaccine with pembrolizumab in relapsing glioblastoma patients","volume":"22","author":"Dutoit","year":"2020","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0405","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11060-015-1837-7","article-title":"Heat shock protein vaccines against glioblastoma: from bench to bedside","volume":"123","author":"Ampie","year":"2015","journal-title":"J. Neurooncol"},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex\u201396 vaccination for recurrent glioblastoma: a phase II, single-arm trial","volume":"16","author":"Bloch","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0415","series-title":"Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination","first-page":"12","author":"Wang","year":"2022"},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0420","doi-asserted-by":"crossref","DOI":"10.4172\/2471-9552.1000125","article-title":"The kynurenine\/tryptophan ratio and glioblastoma patients treated with HSPPC-96 vaccine","volume":"2","author":"Lenzen","year":"2016","journal-title":"Immunotherapy (Los Angel)"},{"key":"10.1016\/j.jns.2026.125787_bb0425","series-title":"Dendritic Cell-based Glioblastoma Vaccines: Advances and Challenges","author":"Zhang","year":"2025"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0430","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0435","series-title":"First Step Results From a Phase II Study of a Dendritic Cell Vaccine in Glioblastoma Patients (CombiG-vax)","first-page":"15","author":"Ridolfi","year":"2024"},{"key":"10.1016\/j.jns.2026.125787_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106336","article-title":"Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: a meta-analysis of randomized controlled trials","volume":"83","author":"Lv","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0445","first-page":"216","volume":"44","author":"Tan","year":"2021","journal-title":"The Efficacy of Dendritic Cell Vaccine For Newly Diagnosed Glioblastoma: A Meta-analysis Of Randomized Controlled Studies"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0450","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","article-title":"WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome","volume":"18","author":"Berneman","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0455","series-title":"Non-invasive Multiplex ELISA Identifies Clinical Responders To Autologous Dendritic Cell Vaccine For Recurrent High-grade Glioma In Phase 1 Clinical Trial","first-page":"242","volume":"71(Suppl 1)","author":"Chandar","year":"2025"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0460","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13073-024-01281-z","article-title":"mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors","volume":"16","author":"Trivedi","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.jns.2026.125787_bb0465","article-title":"The therapeutic effect of mRNA vaccines in glioma: a comprehensive review","volume":"1-13","author":"Afrashteh","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2026.125787_bb0470","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2020.38.15_suppl.3001","article-title":"Oral DNA vaccination targeting VEGFR2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma: safety run-in results\u2014NCT03750071","volume":"38","author":"Wick","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jns.2026.125787_bb0475","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00262-024-03770-x","article-title":"TRP-2\/gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors","volume":"73","author":"Pearson","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jns.2026.125787_bb0480","article-title":"Combination of local immunogenic cell death-inducing chemotherapy and DNA vaccine increases the survival of glioblastoma-bearing mice","volume":"50","author":"Bausart","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jns.2026.125787_bb0485","series-title":"Personalized Cancer Peptide Vaccine Shows Remarkable Promise Against Glioblastoma","author":"Author BG","year":"2024"},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0490","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-014-1676-y","article-title":"Peptide vaccines for the treatment of glioblastoma","volume":"123","author":"Swartz","year":"2015","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0495","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0500","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noy200","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2018","journal-title":"Neuro Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2026.125787_bb0505","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2018.36.15_suppl.2000","article-title":"GAPVAC-101: first-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma","volume":"36","author":"Wick","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.jns.2026.125787_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910765","article-title":"Glioblastoma and immune checkpoint inhibitors: a glance at available treatment options and future directions","volume":"25","author":"Rodriguez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0515","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0520","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.jns.2026.125787_bb0525","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0530","article-title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"4","author":"Omuro","year":"2022","journal-title":"Neurooncol. Adv."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0535","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2022","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.jns.2026.125787_bb0540","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0545","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","article-title":"Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma","volume":"140","author":"Lukas","year":"2018","journal-title":"J. Neurooncol."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0550","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.33378","article-title":"Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial","volume":"127","author":"Reardon","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jns.2026.125787_bb0555","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2019","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0560","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/neuonc\/nox026","article-title":"Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy","volume":"19","author":"Hodges","year":"2017","journal-title":"Neuro Oncol."},{"issue":"Suppl. 6","key":"10.1016\/j.jns.2026.125787_bb0565","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/neuonc\/noab196.204","article-title":"A phase 1 trial of immunoradiotherapy with the IDO enzyme inhibitor (BMS-986205) and nivolumab in patients with newly diagnosed MGMT promoter unmethylated IDHwt glioblastoma","volume":"23","author":"Lukas","year":"2021","journal-title":"Neuro Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jns.2026.125787_bb0570","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps2107","article-title":"A phase I\/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors","volume":"32","author":"Zakharia","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0575","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2026.125787_bb0580","series-title":"Immunotherapeutic Strategies for the Treatment of Glioma","first-page":"73","article-title":"Adoptive cell therapy for glioma","author":"Hoang-Minh","year":"2022"},{"issue":"12","key":"10.1016\/j.jns.2026.125787_bb0585","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2217\/imt-2016-0076","article-title":"Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities","volume":"8","author":"Kuramitsu","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jns.2026.125787_bb0590","series-title":"Adoptive Cell Therapies for Glioblastoma","volume":"3","author":"Bielamowicz","year":"2013"},{"key":"10.1016\/j.jns.2026.125787_bb0595","series-title":"The Abundance of Tumor-infiltrating CD8+ Tissue Resident Memory T Lymphocytes Correlates With Patient Survival in Glioblastoma","first-page":"2454","volume":"10(10)","author":"La Manna","year":"2022"},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1252894","article-title":"Tumor-infiltrating lymphocytes (TILs) from patients with glioma","volume":"6","author":"Liu","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jns.2026.125787_bb0605","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3892\/ol.2016.4944","article-title":"Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients","volume":"12","author":"Han","year":"2016","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0610","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/bjc.2014.162","article-title":"Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma","volume":"110","author":"Han","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.jns.2026.125787_bb0615","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.2023.41.16_suppl.2042","article-title":"Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: an open-label, two-arms, phase 1 study","volume":"41","author":"Yao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jns.2026.125787_bb0620","series-title":"CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression","first-page":"1414","volume":"15(5)","author":"Luksik","year":"2023"},{"key":"10.1016\/j.jns.2026.125787_bb0625","article-title":"First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"issue":"26","key":"10.1016\/j.jns.2026.125787_bb0630","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0635","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"issue":"399","key":"10.1016\/j.jns.2026.125787_bb0640","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0645","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0650","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"7903","key":"10.1016\/j.jns.2026.125787_bb0655","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0660","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jns.2026.125787_bb0665","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.jns.2026.125787_bb0670","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/CJI.0b013e3181b2910f","article-title":"Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma","volume":"32","author":"Dillman","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.jns.2026.125787_bb0675","series-title":"Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated \u03b1\u03b2 T-cells Improves Temozolomide-induced Lymphopenia in Patients With Glioma","first-page":"3921","volume":"37(7)","author":"Kanemura","year":"2017"},{"key":"10.1016\/j.jns.2026.125787_bb0680","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jns.2026.125787_bb0685","series-title":"Unlocking Glioblastoma Secrets: Natural Killer Cell Therapy Against Cancer Stem Cells","first-page":"5836","volume":"15(24)","author":"Du","year":"2023"},{"issue":"45","key":"10.1016\/j.jns.2026.125787_bb0690","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10_Suppl","key":"10.1016\/j.jns.2026.125787_bb0695","doi-asserted-by":"crossref","first-page":"B034","DOI":"10.1158\/2326-6074.TUMIMM24-B034","article-title":"Abstract B034: assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens","volume":"12","author":"Lima","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.jns.2026.125787_bb0700","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","article-title":"Antitumor effects of intracranial injection of B7-H3-targeted CAR-T and CAR-NK cells in a patient-derived glioblastoma xenograft model","volume":"73","author":"Tachi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0705","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-025-01984-3","article-title":"Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells","volume":"13","author":"Meehan","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jns.2026.125787_bb0710","series-title":"Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein","first-page":"8","volume":"90","author":"Saha","year":"2021"},{"key":"10.1016\/j.jns.2026.125787_bb0715","series-title":"Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies","first-page":"547","volume":"15(2)","author":"Hamad","year":"2023"},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0720","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jjco\/hyy170","article-title":"Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives","volume":"49","author":"Taguchi","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0725","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.jns.2026.125787_bb0730","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-22-1382","article-title":"Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers","volume":"28","author":"Kang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jns.2026.125787_bb0735","series-title":"Efficacy of Oncolytic Viral Therapy in Pediatric Brain Tumors: A Systematic Review of Clinical Trials (P3-6.019)","first-page":"5432","volume":"104(7_Suppl_1)","author":"Dhasakeerthi","year":"2025"},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2026.125787_bb0740","doi-asserted-by":"crossref","first-page":"iii43","DOI":"10.1093\/neuonc\/nou209.5","article-title":"Oncolytic polio\/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM): first phase I clinical trial evaluating the intratumoral administration","volume":"16","author":"Desjardins","year":"2014","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0745","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125787_bb0750","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio\u2013rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0755","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.jns.2026.125787_bb0760","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0765","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ymthe.2024.01.035","article-title":"Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice","volume":"32","author":"Shin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jns.2026.125787_bb0770","series-title":"Adenovirus-neutralizing and Infection-promoting Activities Measured in Serum of Human Brain Cancer Patients Treated With Oncoelytic Adenovirus Ad5-\u039424.RGD","first-page":"854","volume":"26(2)","author":"van der Meulen-Muileman","year":"2025"},{"issue":"9","key":"10.1016\/j.jns.2026.125787_bb0775","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0780","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.ymthe.2023.08.009","article-title":"Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: translational developments from rodents to glioma patients","volume":"31","author":"Faisal","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jns.2026.125787_bb0785","article-title":"The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wei","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0790","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/1078-0432.CCR-08-2130","article-title":"Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme","volume":"15","author":"Quinn","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jns.2026.125787_bb0795","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0800","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1038\/s41598-024-55072-y","article-title":"Integrating imaging and genomic data for the discovery of distinct glioblastoma subtypes: a joint learning approach","volume":"14","author":"Guo","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0805","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43246-024-00721-y","article-title":"Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma","volume":"6","author":"Mokarram","year":"2025","journal-title":"Commun. Mater."},{"key":"10.1016\/j.jns.2026.125787_bb0810","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0815","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"issue":"2","key":"10.1016\/j.jns.2026.125787_bb0820","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","article-title":"Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme","volume":"103","author":"Maier-Hauff","year":"2011","journal-title":"J. Neurooncol"},{"issue":"23","key":"10.1016\/j.jns.2026.125787_bb0825","doi-asserted-by":"crossref","first-page":"13160","DOI":"10.3390\/ijms222313160","article-title":"Design of biopolymer-based interstitial therapies for the treatment of glioblastoma","volume":"22","author":"Pena","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2026.125787_bb0830","series-title":"Spatial Patterning and Immunosuppression of Glioblastoma immune contexture in hypoxic niches [Preprint]","author":"Sattiraju","year":"2022"},{"key":"10.1016\/j.jns.2026.125787_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.760055","article-title":"Trametinib inhibits the growth and aerobic glycolysis of glioma cells by targeting the PKM2\/c-Myc axis","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jns.2026.125787_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107528","article-title":"Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials","volume":"212","author":"Pinto-Fraga","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.jns.2026.125787_bb0845","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jns.2026.125787_bb0850","article-title":"Effects of the gut microbiota and its metabolite short-chain fatty acids on endometriosis","volume":"14","author":"Liu","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0855","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12974-025-03434-2","article-title":"Gut microbiota and their influence in brain cancer milieu","volume":"22","author":"BharathwajChetty","year":"2025","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0860","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12088-021-00962-2","article-title":"Alterations of the gut microbiome in recurrent malignant gliomas patients received bevacizumab and temozolomide combination treatment and temozolomide monotherapy","volume":"62","author":"Zhu","year":"2022","journal-title":"Indian J. Microbiol."},{"issue":"1","key":"10.1016\/j.jns.2026.125787_bb0865","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12967-023-04042-5","article-title":"Gut microbiota mediated the individualized efficacy of temozolomide via immunomodulation in glioma","volume":"21","author":"Hou","year":"2023","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.jns.2026.125787_bb0870","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molmed.2024.08.008","article-title":"Exploiting the gut microbiome for brain tumour treatment","volume":"31","author":"Keane","year":"2025","journal-title":"Trends Mol. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:01:22Z","timestamp":1793739682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":174,"alternative-id":["S0022510X26000699"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125787","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immune awakening: Transformative strategies against brain tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125787"}}